Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
April 06 2018 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, will present two posters summarizing
preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at
the upcoming AACR meeting at McCormick Place in Chicago, Illinois.
Session, date, time, and location (for both
posters):
- Session Category (Title): Clinical Research
(Adoptive Cell Therapy 2)
- Date: Monday Apr 16, 2018
- Time: 1:00 PM - 5:00 PM (CDT)
- Location: McCormick Place South, Exhibit Hall
A, Poster Section 24
Poster 1 – MAGE-A4
- Title: Affinity-enhanced T-cell receptor (TCR)
for adoptive T-cell therapy targeting MAGE-A4
- Poster Board Number: 21
- Permanent Abstract Number: 2562
Poster 2 – MAGE-A10
- Title: Selection of affinity-enhanced T-cell
receptors for adoptive T-cell therapy targeting MAGE‑A10
- Poster Board Number: 23
- Permanent Abstract Number: 2564
Adaptimmune will also have a booth (#3700) in the Exhibit
Hall.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T‑cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP
across several solid tumor indications. GlaxoSmithKline
plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively
license the right to research, develop, and commercialize
Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September
2017. Transition of this program to GSK is ongoing. The
Company is located in Philadelphia, USA and Oxfordshire, U.K. For
more information, please visit http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Annual Report filed on
for 10-K with the Securities and Exchange Commission (SEC) on March
15, 2018 and our other SEC filings. The forward-looking statements
contained in this press release speak only as of the date the
statements were made and we do not undertake any obligation to
update such forward‑looking statements to reflect subsequent events
or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Sep 2023 to Sep 2024